EGFR and neoplasm: Several non-mutually exclusive mechanisms that limit osimertinib response have been identified in the context of systemic disease, with most of these directly attributed to genetic alterations in the tumor cells (e.g., subtype of EGFR mutation43,44 and other co-occurring mutations45) or adaptive molecular changes by cancer cells in response to drug alone.